Gamma-aminobutyric acid type A receptor alpha-2, alpha-3, and alpha-5 subunit-containing complexes (GABA-A receptor α2/3/5 subtypes)

Gamma-aminobutyric acid type A (GABA-A) receptors are pentameric ligand-gated chloride channels that serve as the primary mediators of fast inhibitory neurotransmission in the mammalian central nervous system (Rudolph & Knoflach, 2011, Nature Reviews Drug Discovery). This specific target grouping includes receptors containing α2, α3, or α5 subunits, typically associated with β and γ2 subunits, which are distinct from the more prevalent α1-containing receptors (Mohler, 2006, Pharmacology & Therapeutics). While α1 subunits primarily mediate sedative, hypnotic, and amnestic effects, α2 and α3 subunits are the principal mediators of anxiolytic and muscle-relaxant activities, making them high-priority targets for treating anxiety and chronic pain without the dose-limiting sedation of traditional benzodiazepines (Atack, 2011, Advances in Pharmacology). The α5 subunit is predominantly expressed in the hippocampus and is critically involved in learning and memory processes; consequently, α5-selective negative allosteric modulators are being investigated as cognitive enhancers for conditions like Alzheimer's disease and Down syndrome (Braudeau et al., 2011, Science Translational Medicine). Developing drugs with high selectivity for these subunits over the α1 subtype remains a major strategy in neuropharmacology to improve the therapeutic index of GABAergic modulators (Sieghart & Savic, 2018, Frontiers in Pharmacology). Clinical candidates such as TPA023 and Basmisanil have demonstrated the feasibility of targeting these specific subtypes to achieve therapeutic effects while minimizing the side effects associated with non-selective modulation (Atack, 2010, Drugs of the Future).

Other names

α2/α3/α5-selective GABA-A receptorsNon-alpha-1 GABA-A receptorsBenzodiazepine-sensitive GABA-A receptor subtypes (excluding alpha-1)GABRA2/GABRA3/GABRA5-containing receptors

Positive allosteric modulation (PAM) at the benzodiazepine binding site to enhance GABA-mediated chloride influx for α2 and α3 subunits (anxiolysis/analgesia), or negative allosteric modulation (NAM) for α5 subunits to enhance cognitive function by reducing tonic inhibition.